The antiviral activity of tumor necrosis factor in HeLa cells is not mediated by interferons. Studies with TNF-resistant variants. 1988

S Gessani, and S E Johnson, and S McCandless, and C Baglioni
Department of Biological Sciences, State University of New York, Albany.

Tumor necrosis factor (TNF) has a relatively modest antiviral activity in HeLa cells, when compared to that of interferon (IFN). Addition of antisera neutralizing IFN-alpha or beta did not reduce the antiviral activity of TNF. Furthermore, we determined with a sensitive hybridization assay that less than one molecule of IFN-beta 1 mRNA could be present per TNF-treated cell. HeLa cell variants resistant to the TNF cytocidal activity were selected. These variants had TNF receptors with a dissociation constant similar to that of parental cells. Three cloned variants tested did not respond to the antiviral activity of TNF, but responded to IFN-alpha. Surprisingly, two of the variants did not respond to IFN-gamma. This suggests that the pathways mediating the cytocidal activity of TNF and the response to IFN-gamma share some common step. TNF induced transcription of IFN-beta 2 in resistant variants, indicating that this cytokine does not contribute to the antiviral activity of TNF.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004686 Encephalomyocarditis virus The type species of CARDIOVIRUS causing encephalomyelitis and myocarditis in rodents, pigs, and monkeys. Infection in man has been reported with CNS involvement but without myocarditis. EMCV
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

S Gessani, and S E Johnson, and S McCandless, and C Baglioni
November 1997, The Journal of experimental medicine,
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
March 1989, Antiviral research,
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
January 1995, Journal of inflammation,
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
February 1988, Journal of immunology (Baltimore, Md. : 1950),
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
August 1989, Cellular immunology,
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
January 1982, Nihon rinsho. Japanese journal of clinical medicine,
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
November 1992, Journal of immunology (Baltimore, Md. : 1950),
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
May 1989, Immunology letters,
S Gessani, and S E Johnson, and S McCandless, and C Baglioni
October 1989, The American journal of physiology,
Copied contents to your clipboard!